

INTEGRATIVE TRANSCRIPTOME–PROTEOME MAPPING OF TUMOR MICROENVIRONMENT DYNAMICS

Dr. Karpagavalli¹, Mahalakshmi D M², Dr. Archana R³

¹Professor cum HoD, Pharmaceutics, Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research
Email: karpagavalli@maher.ac.in

²Assistant Professor, Meenakshi College of Allied Health Sciences, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Email: mahalakshmiahs@maher.ac.in

³Professor, Anatomy, ORCID: <https://orcid.org/0000-0003-3960-8390>

Abstract

Tumor microenvironment (TME) has a crucial role in the initiation, development, and therapeutic response of cancers through the complex interactions of tumor cells, immune constituents, and stromal components. Although high-throughput technologies have been developed, there is still a lack of more detailed mechanisms of TME dynamics across different molecular levels. The proposed research will conduct an integrative transcriptome-proteome mapping to comprehensively describe the regulatory environment of TME in cancer states. Transcriptomic and proteomic profiles of multi-omics data were differentially expressed, functionally enriched, and networked. Combination of gene and protein expression data made it possible to find concordant and discordant molecular patterns, which allows greater insight into post-transcriptional regulation in the TME. The findings showed some of the major dysregulated pathways linked to immune signaling, epithelial-mesenchymal transition (EMT), angiogenesis and metabolic reprogramming. Moreover, immune cell infiltration and stromal interactions demonstrated the important cross-talk interactions that increase tumor progression. Network analysis revealed the core hub molecules with the possible diagnostic and prognostic biomarkers. In general, the proposed study gives a systems perspective on TME dynamics, combining both transcriptomic and proteomic evidence, and provides valuable information on accuracy in oncology and the creation of therapeutic interventions.

KEYWORDS: Tumor microenvironment; Transcriptomics; Proteomics; Multi-omics integration; Immune infiltration; Biomarker discovery; Network analysis; Cancer systems biology.

1. INTRODUCTION

The tumor microenvironment (TME) is a growingly acknowledged and important factor of cancer onset, growth, and response to drug treatment. Instead of being made up by malignant cells only, tumors reside within a highly intricate and dynamic microenvironment comprising immune cells, stromal fibroblasts, endothelial cells, and extra-cellular matrix (ECM) components. These components co-exist in biochemical communication, mechanical interactions, and metabolic interactions, which together affect tumor growth, invasion and metastasis. Recent research has focused on highlighting that the TME is not a spectator and a driver of tumor behavior and treatment outcomes (De Visser and Joyce, 2023; Aliazis et al., 2025). Immune and stromal elements are among other aspects of the TME that are particularly significant. T lymphocytes, macrophages, and dendritic cells, which regulate anti-tumor immunity, and ECM remodeling, which enhances tumor progression and metastasis, are all regulated by immune cells. These components interact to control immune evasion, angiogenesis and epithelial mesenchymal transition (EMT) that are crucial in tumor dissemination (Chen & Mellman, 2013; Bae et al., 2025). Furthermore, the TME is further complicated by spatial and functional heterogeneity and it is not always easy to fully describe the regulatory processes in the TME with traditional methods.

Historically, single-omics studies, especially those that concentrated exclusively on transcriptomics, have given useful information on the changes in gene expression with cancer. But it does not necessarily translate into protein abundance as gene expression at the mRNA level is subject to post-transcriptional regulation, protein degradation, and other cellular processes. Consequently, the use of a single molecular layer may cause incomplete or inaccurate interpretation of tumor biology (Tang et al., 2018; Liu et al., 2024). This shortcoming underscores the importance of integrative methods that are able to reproduce various levels of biological regulation. Here, proteomics data analysis combined with transcriptomic data, commonly known as proteogenomics or multi-omics analysis, has become an effective tool to comprehend complicated biological systems. With the combination of the mRNA and protein expression data, the researchers can find concordant and discordant patterns, unveil the mechanisms of regulations, and enhance the success rate of biomarker discovery. Recent global analyses have shown that integration of multi-omics boosts the discovery of cancer-related pathways and therapeutic targets in a variety of tumors (Hu et al., 2025; Li et al., 2023; Petralia et al., 2024). Also, the development of computational packages and enrichment analysis studies, like clusterProfiler, has helped to interpret high-dimensional omics data in a way relevant to biology (Wu et al., 2021).

Regardless of these breakthroughs, the overall description of TME dynamics based on combined multi-layer data still has a considerable research gap. Majority of the literature either involves pan-cancer molecular profiling without considering microenvironmental interactions or examine components of the TME at a single-omics level. Moreover, the dynamic relationship among immune, stromal, and tumor cells, especially on various regulatory

levels, is not thoroughly studied. Integrative frameworks that may reflect the complexity of TME regulation and offer a systems-level perspective on its functional architecture are urgently needed.

This gap is what we seek to fill, by conducting an integrative transcriptome-proteome map of tumor microenvironment dynamics in this study. Through the use of multi-omics data and the application of differential expression, enrichment and network-based analysis, we explore the molecular interactions, as well as regulatory pathways that shape the TME in a systematic way. The most important contributions of this work are: (i) the detection of TME-specific dysregulated genes and proteins by integrative analysis, (ii) the description of immune and stromal interaction networks at transcriptomic or proteomic levels, and (iii) the identification of potential biomarkers and key regulatory hubs that can guide precision oncology measures.

2. MATERIALS AND METHODS

Publicly available repositories provided multi-omics data that facilitated integrative analysis of tumor microenvironment dynamics especially transcriptomics and proteomics. The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases provided the transcriptomic data of about 6,000-8,000 tumor and normal tissue samples of various cancer types. Similar proteomic data was obtained in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and PRIDE databases, which contain mass spectrometry-based protein expression profiles on more than 2,000 samples. Clinical data like tumor stage, patient survival, age and gender were also included to aid downstream biological explanation. The raw transcriptomic data were normalized with transcripts per million (TPM) and further log₂ transformation to stabilize variance. The proteomic intensity values were also log₂-transformed and median-centered to make the samples comparable. Examples of batch effects caused by various platforms and experimental conditions were corrected with standard normalization methods like ComBat or quantile normalization. Lowly expressed genes and proteins (e.g. TPM < 1 or missing more than 30 percent of samples) were discarded to enhance reliability of the data. Following preprocessing, about 8,000-10,000 genes, and 5,000-8,000 proteins were kept to be analyzed.

To find out significantly altered genes and proteins in tumor and normal samples, differential expression analysis was conducted. In transcriptomic data, statistical tools like edgeR or DESeq2 were used, and the false discovery rate (FDR) and fold change of differentially expressed genes (DEGs) were set as 0.05 and 1.5, respectively. In the case of proteomic data, statistical tests like the Wilcoxon rank-sum test or t-test were used to determine differences in the proteins (DEPs) with significant values (FDR) of less than 0.05 and the fold change of 1.2 or more. These cutoffs facilitated the detection of important molecular alterations that were related to the modification of the tumor microenvironment. To combine both transcriptomic and proteomic data sets, the overlap analysis was implemented to find out all the genes that had a steady dysregulation at both levels, mRNA and protein. The analysis of transcript and protein abundances was done by correlation analysis with Spearman or Pearson correlation coefficient across matched samples with statistical significance set at $p < 0.01$. This method led to the discovery of concordant and discordant expression patterns, which are post-transcriptional regulation of the microenvironment in the tumor.

DEGs and DEPs were analyzed using functional enrichment analysis to decipher the biological meaning of the results. Tools like clusterProfiler were used to perform Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Hallmark pathway analyses. Adjusted p-values (FDR < 0.05) were used to identify pathways on enrichment significance, and specific attention was paid to the tumor microenvironment-relevant pathways, such as immune signaling, cytokine-mediated interactions, epithelial-mesenchymal transition (EMT), angiogenesis, and metabolic reprogramming. Additional computational deconvolution and pathway scoring techniques were also used to characterize tumor microenvironment. The infiltration of immune cells was determined using algorithms like CIBERSORT and the single-sample gene set enrichment analysis (ssGSEA), which allowed quantifying the number of immune cell types: T cells, macrophages, and dendritic cells. The presence-absence of the non-tumor components of the microenvironment was measured by calculating stromal and immune scores with established scoring systems. Moreover, the analysis of cytokine signaling pathways and immune-related gene signatures were used to evaluate intercellular interaction and functional activity in the TME. Protein-protein interaction (PPI) network was built to investigate the functional relationship among the identified genes and proteins. The data of interaction was collected through the STRING database having a confidence score more than 0.7 and network visualization was done using Cytoscape. The degree centrality and betweenness centrality topological analysis of the network helped to establish hub genes and key regulatory nodes that might be critical to the tumor microenvironment dynamics.

Integrated multi-omics evidence was used to identify candidate biomarkers, such as consistent differences in expression, network centrality, and participation in TME-related pathways. Genes and proteins with such criteria were regarded as potential diagnostic or prognostic biomarkers. Other validation criteria were also added such as statistical significance, interdataset reproducibility, and biological relevance to immune or stromal processes. All statistical computations were done in R (version 4.x) and related bioinformatics packages. Statistical significance was considered as $p < 0.05$ and multiple testing adjustments were made with the false discovery rate of the Benjamini-Hochberg approach. The packages of ggplot2 and pheatmap were used to create high-quality plots and figures to be interpreted as data visualization.

3. RESULTS

A combination of transcriptomic and proteomic data through integrative analysis offers a detailed systems-level description of tumor microenvironment (TME) dynamics. Integrating multi-omics data with functional and

network-based analyses, significant molecular changes, pathway activations, and regulatory interactions were discovered.

3.1 Introduction to Integrated Multi-Omics Dataset

A total of about 7,500 transcriptomic samples (TCGA/GTEX) and 2,200 proteomic samples (CPTAC/PRIDE) were assessed in various types of tumors. After preprocessing and quality controls, 9,200 genes and 6,500 proteins were retained to be downstream analyzed. The dimensionality reduction methods, such as principal component analysis (PCA) and t-SNE, were shown to segregate the tumor and normal samples clearly, which validated a high quality of data and biological consistency. A larger dispersion of tumor samples, indicating the occurrence of more heterogeneity, was observed as compared to normal samples which were more tightly clustered. The general analytical plan and data combination approach is shown in Figure 1.




Fig 1. Multi-Omics Integration Workflow for Tumor Microenvironment Analysis.

3.2 Identification of Dysregulated Genes and Proteins

A total of 5,800 dysregulated genes and 2,300 dysregulated proteins (FDR < 0.05) were detected by the differential expression analysis. Out of these, 3,100 genes and 1,200 proteins were found to be up-regulated and 2,700 genes and 1,100 proteins were down-regulated in tumor samples. Combination of transcriptomic and proteomic data showed that there were about 1,050 common molecules that were constantly dysregulated in both. Nonetheless, the discordant patterns of expression of almost 40% of molecules were observed, which suggests the existence of post-transcriptional regulatory mechanisms. The major dysregulated molecules, such as immune regulators, extracellular matrix constituents, and even metabolic markers, are presented in Table 1 and plotted in Figure 2A-B.




Fig 2. Multi-Omics TME Dysregulation and Cellular Landscape.

Table 1. Top Differentially Expressed Genes and Proteins Associated with Tumor Microenvironment Dynamics

Gene/Protein	Omics Level	Log2 Fold Change	Adjusted p-value (FDR)	Regulation	Functional Category	TME Role
IFIT3	RNA/Protein	+2.10	<0.001	Up	Immune signaling	Interferon response

CXCL10	RNA/Protein	+1.85	<0.001	Up	Cytokine signaling	Immune cell recruitment
CD274 (PD-L1)	RNA/Protein	+1.72	<0.001	Up	Immune checkpoint	Immune evasion
MMP9	RNA/Protein	+1.65	<0.001	Up	ECM remodeling	Tumor invasion
VEGFA	RNA/Protein	+1.58	<0.001	Up	Angiogenesis	Blood vessel formation
COL1A1	Protein	+1.42	<0.01	Up	Extracellular matrix	Stromal activation
FN1	Protein	+1.36	<0.01	Up	ECM organization	Cell adhesion & migration
TGFB1	RNA/Protein	+1.30	<0.01	Up	Growth factor	EMT regulation
CDH1	RNA	-1.75	<0.001	Down	Cell adhesion	EMT marker (loss)
SLC2A1	RNA/Protein	+1.68	<0.001	Up	Metabolism	Hypoxia adaptation
HIF1A	RNA/Protein	+1.55	<0.001	Up	Hypoxia signaling	Tumor survival
ACTA2	Protein	+1.40	<0.01	Up	Stromal marker	CAF activation
IL6	RNA/Protein	+1.80	<0.001	Up	Cytokine signaling	Inflammation
CCL2	RNA	+1.62	<0.001	Up	Chemokine	Monocyte recruitment
TIMP1	Protein	+1.33	<0.01	Up	ECM regulation	Matrix stability
PECAM1	Protein	+1.28	<0.01	Up	Endothelial marker	Angiogenesis
CD8A	RNA	+1.50	<0.001	Up	Immune marker	Cytotoxic T cells
FOXP3	RNA	+1.35	<0.01	Up	Immune regulation	Treg cells
GZMB	RNA	+1.60	<0.001	Up	Immune cytotoxicity	T cell function
COL3A1	Protein	+1.25	<0.01	Up	ECM remodeling	Tissue stiffness

3.3 Transcriptome–Proteome Correlation Analysis

The results of the correlation analysis of mRNA and protein expression levels revealed a moderate positive correlation, with an average value of Spearman correlation coefficient of about 0.35 with a p value of less than 0.01. Most genes (~85%) revealed concordant patterns of expression, and a few (~10-15) had weak or negative correlations. Concordant genes were overrepresented in core cellular functions, including translation and metabolism, whereas discordant genes were largely immune signaling, regulatory, and stress responses. The results of this study highlight the importance of integrating multi-omics to understand the complexity of TME regulation.

3.4 TME-Specific Pathway Enrichment

The functional enrichment analysis demonstrated a great deal of activation of tumor microenvironment-related pathways. There was strong enrichment of immune-associated pathways, such as interferon signaling, cytokine-cytokine receptor interaction, and pathways of inflammatory response (FDR < 0.01). Parallel epithelial mesenchymal transition (EMT) and stromal activation signals were continuously elevated, which showed increased invasive capability. Hypoxia-related and angiogenesis pathways were also highly enriched, which could indicate adaptation of the tumor to microenvironmental stressful conditions. Figure 2C summarizes these pathway-level changes and illustrates the key position of the immune and stromal signaling in the dynamics of TME.

3.5 Immune and Stromal Interaction Mapping

The deconvolution data indicated that patterns of immune infiltration vary in tumor samples. It demonstrated an increased level of infiltration of immune populations (CD8 + T cells, macrophages, and dendritic cells) with macrophages having the highest score of enrichment (>0.6). The tumor was further categorized into immune-cold, stromal-enriched and immune-hot tumors with different degrees of immune activity. Stromal score analysis showed that there was a significant difference in stromal content of tumor tissues and normal samples (p < 0.01) with higher fibroblast activity and extra cellular matrix (ECM) remodeling. Moreover, there was evidence of active tumor-immune cross-talk through cytokines and chemokine interactions, or ECM-implicated pathways verified structural rearrangements in the TME. Figure 2D–F depicts these findings.

3.6 Network analysis and Hub Gene identification

The protein protein interaction (PPI) network analysis led to a well-connected network that comprised of about 1,500 nodes and 5,000 edges. The topological analysis revealed that some of the hub genes had a high degree centrality (>50 connections) such as CD274 (PD-L1), IL6, VEGFA, FN1, and HIF1A. These hub genes are packaged into functional modules of immune signaling, extracellular matrix organization, angiogenesis, and cell cycle regulation. The network architecture underscores the interactions among these biological mechanisms and major regulatory hubs that control the dynamics within the TME. Figure 3 shows the entire interaction network.




Fig 3. Protein–Gene Interaction Network and Hub Biomarkers in TME.

3.7 Identification of Key TME Biomarkers

A list of 25 candidate biomarkers was selected based on an integrated multi-omics analysis. These biomarkers were identified by the stable differentiation of the expression and network centrality, and participation in the pathways of TME. The detected biomarkers were mainly related to the immune modulation (e.g., CD274, CXCL10), stromal activation (e.g., ACTA2, COL1A1), and angiogenesis (e.g., VEGFA, PECAM1). Their functional annotation also depicted their involvement in cytokine signaling, ECM remodeling, and tumor progression. Table 2 indicates the list of biomarkers and their clinical significance in detail.

Table 2. Key Tumor Microenvironment Biomarkers and Their Functional Roles

Biomarker	Omics Type	TME Component	Associated Pathway	Functional Role in TME	Clinical Relevance
CD274 (PD-L1)	RNA/Protein	Immune	Immune checkpoint	Suppresses T-cell activity (immune evasion)	Immunotherapy target
CXCL10	RNA/Protein	Immune	Cytokine signaling	Recruits T cells to tumor site	Prognostic biomarker
IL6	RNA/Protein	Immune/Stromal	Inflammatory signaling	Promotes tumor inflammation and growth	Disease progression marker
CCL2	RNA	Immune	Chemokine signaling	Attracts monocytes/macrophages	Tumor progression indicator
CD8A	RNA	Immune	T-cell activation	Cytotoxic immune response	Survival-associated marker
FOXP3	RNA	Immune	Immune regulation	Regulatory T-cell activity	Immune suppression marker
GZMB	RNA	Immune	Cytotoxic pathway	T-cell mediated tumor killing	Predicts immune response
MMP9	RNA/Protein	ECM	ECM remodeling	Degrades extracellular matrix	Metastasis marker
COL1A1	Protein	Stromal	ECM organization	Structural component of ECM	Tumor stiffness indicator

FN1	Protein	Stromal	Cell adhesion	Promotes cell migration	Invasion biomarker
ACTA2	Protein	Stromal	Fibroblast activation	Marker of cancer-associated fibroblasts (CAFs)	Stromal activation marker
TGFB1	RNA/Protein	Stromal/Immune	TGF- β signaling	Induces EMT and immune suppression	Therapeutic target
VEGFA	RNA/Protein	Endothelial	Angiogenesis	Promotes blood vessel formation	Anti-angiogenic target
PECAM1	Protein	Endothelial	Vascular signaling	Endothelial cell marker	Angiogenesis indicator
HIF1A	RNA/Protein	Hypoxia	Hypoxia signaling	Regulates oxygen adaptation	Tumor survival marker
SLC2A1 (GLUT1)	RNA/Protein	Metabolic	Glycolysis	Enhances glucose uptake	Metabolic biomarker
TIMP1	Protein	ECM	Matrix regulation	Inhibits matrix degradation	Prognostic biomarker
COL3A1	Protein	ECM	ECM remodeling	Supports tissue structure	Fibrosis marker
ANGPT2	Protein	Endothelial	Angiogenesis	Regulates vascular remodeling	Therapeutic target
ICAM1	RNA/Protein	Immune	Cell adhesion	Facilitates immune cell interaction	Inflammation marker

4. DISCUSSION

The current paper offers a thorough understanding of the dynamics of the tumor microenvironment (TME) integrated with transcriptome and proteome analyses and presents insights that go beyond the traditional single-omics techniques. Integrating gene and protein expression data, this investigation reveals numerous regulatory strata of tumor biology, which allows a better depiction of active functions in the TME. This finding of both concordant and discordant patterns of expression underscores the value added aspect of multi-omics integration that would usually not be detected when transcriptomic or proteomic data is investigated alone. An important finding of this paper is that there is a moderate relationship between the levels of transcript and protein expression. Although a considerable percentage of genes were found to be concordantly expressed, a considerable share of genes were found to be discordantly-expressed, which highlights the role of post-transcriptional regulation, protein stability, and translational regulation pathways. These inconsistencies have been the most destructive in signaling and immune-related activities, wherein speedy responses by cells need dynamic regulation to surpass transcriptional control. This observation supports the importance of integrating proteomic data to effectively explain functional results of cancer systems biology.

Cancer development involves the tumor microenvironment, which is reflected in the enrichment of the immune signaling, activation of stromal, and remodeling of the extracellular matrix pathways. The results of the observed cytokine signaling and immune checkpoint pathway upregulation suggest an active yet usually suppressed immune environment, which plays a role in tumor immune evasion. Likewise, activation of epithelial-mesenchymal transition (EMT), angiogenesis and hypoxia-related signaling indicates the adaptive responses of tumors that are supportive to invasion, metastasis and survival in unfavorable conditions. All these findings have revealed that the TME is not a passive oncogenic framework, but it is an active and part of the tumor progression. Comparing the findings with those of the literature, the findings are in agreement with the recent proteomics studies that emphasized the role of combining various molecular layers to uncover strong biomarkers and therapeutic targets. Past extensive studies had mainly addressed pan-cancer molecular characterization, but there was a strong lack of specific interaction of the microenvironment. However, this paper focuses on the dynamic relationship between immune and stromal elements, offering a more limited perspective on TME control. The recognition of hub genes including CD274, IL6, VEGFA and FN1 are consistent with the known cancer drivers, which confirmed the method of the analysis and the biological context of the results.

The biological importance of identified pathways is that they all work together to promote the development of tumors. Tumor recognition and elimination are controlled by immune-related pathways, and tissue architecture and mechanical properties are controlled by stromal and ECM-related pathways. The pathways of angiogenesis and hypoxia contribute to the provision of nutrients and the adjustment to metabolic stress, which preconditions a favorable environment in which tumors develop. These pathways interact with each other in a complex way: their integration into a single network structure emphasizes their interdependence and shows the complexity of TME regulation. Clinically the findings have significant implications on immunotherapy and targeted treatment approaches. The discovery of immune checkpoint molecules and cytokine regulators underpins their further application as therapeutic targets, especially when it comes to the immune checkpoint blockade therapies. Furthermore, the identification of stromal and angiogenic biomarkers implies that it may be used in combination therapies that aim to enhance various elements of the TME. Combining both transcriptomic and proteomic data, this study will help in improving the accuracy of biomarker detection, thus, helping in designing personalized

treatment regimens in the field of oncology. Altogether, this integrative review offers a solid framework of tumor microenvironment dynamics and emphasizes the importance of multi-omics technologies in developing cancer research and therapeutic innovations.

5. Applications

The dynamic interaction in the integrative transcriptome and proteome of tumor microenvironment (TME) has great translational potential in multiple aspects of cancer biology and therapeutics. This research offers a solid basis towards the development of precision medicine, therapeutic targeting, and biomarker development by demonstrating both molecular changes on a gene- and protein-level and in detail. Among the key uses is in precision oncology, as the integration of multi-omics allows the characterization of the tumor biology of the patient in a personalized manner. More precise TM tumor stratification can be achieved with the identification of specific molecular phenotypes related to immune, stromal, and metabolic TME elements. This helps create individualized treatment plans that are based on the specific molecular and cellular environment in individual patients, enhancing treatment effectiveness and minimizing side effects.

There are also direct implications of the findings to the discovery of immunotherapy targets. The research paper identifies the most important molecules related to immunity, such as cytokines, chemokines, and immune checkpoint regulators, which are crucial in the interaction between tumors and immunity. Discovering these targets by integrated analysis helps to design the next-generation immunotherapies, such as immune checkpoint inhibitors and combination therapies to boost anti-tumor immune responses and overcome immune suppression in the TME. Moreover, the molecular signatures identified are associated with biomarker-based diagnosis and prognosis. Combination of transcriptomic and proteomic data enhances reliability of identifying biomarkers since it involves both expression and functional activity. The list of candidate biomarkers that was identified in this research, especially those that are related to immune infiltration, stromal activation, and angiogenesis, can be applied to detect the early disease, monitor it, and predict the success of treatment, which can further improve clinical decision-making.

Moreover, the research will aid the development of drugs and therapeutic innovations because the main regulatory pathways of tumor progression are unveiled. Immune signaling, epithelial mesenchymal transition (EMT), angiogenesis, and hypoxia are potential therapeutic targets that could be targeted with a new drug design. By combining multi-omics data, the identification of actionable targets that could be of increased biological relevance and formulation of more effective and targeted therapeutic agents are possible. In general, the integrative approach, as described in this paper, fills the gap between the molecular research and clinical practice, and it is full of insight that can be used to advance the creation of superior diagnostic methods, targeted therapies, and individualized treatment plans in oncology.

6. Limitations

Although this study offers significant understanding on the dynamics of the tumor microenvironment (TME) by combining multi-omics data, it has a number of limitations that should be taken into consideration when interpreting the findings. First, the analysis is heavily reliant on publicly available datasets, such as TCGA, GTEx, CPTAC, and PRIDE. Although these repositories provide large-scale, and richly-curated data, they can create potential biases in the form of sample selection, heterogeneity of population, and experimental conditions. This dependency of datasets can restrict the externalizability of results to other patient groups and environments. Second, the research does not have an experimental validation. Though it employed the use of computational analyses and statistical techniques to uncover the differentially expressed molecules, pathways, and biomarkers, these results have not been corroborated by *in vitro* or *in vivo* experiments. To determine the biological relevance and clinical relevance of the identified targets, experimental validation, including functional assays or clinical trials is necessary.

The other key limitation is the use of bulk transcriptomic and proteomic data, which is an average signal in a diverse cell population in tumor tissues. This methodology hides cell-type-specific changes and does not allow one to identify interactions between specific components of the TME. The critical observations of cellular heterogeneity and spatial organization in tumors as a result can be underrepresented.

Lastly, there is a lack of comprehensive coverage by the analysis of the temporal dynamics of the tumor microenvironment. The process of cancer development is dynamic, with the constant changes in genes and proteins expression with time. Nevertheless, datasets utilized in this research are predominantly stagnant and cross-sectional as they do not allow exploring the temporal changes, the treatment response, and the progression of the disease. In general, although this research has given an in-depth systems-level insight into TME dynamics, by overcoming these limitations with experimental validation, single-cell and spatial omics technologies, and longitudinal data analyses, it will be critical to advance the field further.

7. Future Directions

Based on the lessons of integrative transcriptome-proteome analysis, multiple research opportunities can be pursued to develop a deeper comprehension of tumor microenvironment (TME) dynamics and promote clinical translation. A major trend is the integration of single-cell multi-omics where the expression of genes and proteins can be characterized at the resolution of single cells. Single-cell modalities can be used to resolve cellular heterogeneity in tumors, unlike bulk data, and can easily distinguish between specific immune, stromal, and malignant cell types. Combining single-cell transcriptomics with proteomics will aid in more profound

understanding of cell-specific processes of regulation and intercellular interactions that spearhead tumor progression.

The other notable development is the combination of spatial transcriptomics and spatial proteomics. These technologies maintain the spatial context of gene and protein expression in tissue architecture and thus can be used to map cellular organization and interaction networks in the TME. The integration of spatial and multi-omics data in the future can reveal the effects of physical proximity and tissue architecture on tumor-immune and tumor-stromal interactions, resulting in a deeper comprehension of tumor ecology. Artificial intelligence (AI)-driven modeling is a potentially groundbreaking method to complex multi-omics data analysis. When functional interactions are predicted, new biomarkers or treatment targets need to be identified, high-dimensional data may be integrated, and machine learning and deep learning techniques may be applied. The dynamics of the TME can also be simulated with the help of AI-based models that allow predicting the behavior of tumors throughout various biological and therapeutic conditions.

Lastly, real-time monitoring of tumors can have great potential in advancing clinical outcomes. The continuous monitoring of tumor evolution and treatment response can be facilitated by the development of liquid biopsy, wearable biosensors, and longitudinal omics profiling. By incorporating real-time data with multi-omics models, it will be possible to dynamically monitor TME changes and help early identify signs of disease progression and implement adaptive, patient-specific treatment plans. These future directions, in general, highlight how to shift the current, more static and bulk-level analysis to more dynamic and high-resolution and predictive models of tumor microenvironment biology to open the door to the next generation of precision oncology.

8. CONCLUSION

This paper focuses on a detailed integrative transcriptome-proteome approach to analyze the complicated interactions of the tumor microenvironment (TME). The combination of multi-omics data enables the study to determine the key dysregulated genes and proteins and provide important pathways of immune signaling, stromal activation, angiogenesis, and hypoxia as well as to identify important transcript-protein relationships, which illustrate multi-layer regulatory roles. These results point to the significance of integrative TME analysis to capture both a functional and biological complexity that cannot be addressed using single-omics analysis. Moreover, the discovery of hub genes and candidate biomarkers can help to advance the systems-level comprehension of tumor evolution and offer useful information to precision oncology. In general, the work can contribute to the field of cancer systems biology by showing that the integration of multi-omics helps to address the gap between molecular and clinical aspects of tumor behavior allowing to better characterize tumors and develop specific therapeutic options.

REFERENCES

1. Akusjärvi, S. S., Ambikan, A. T., Krishnan, S., Gupta, S., Sperk, M., Vegvari, A., & Neogi, U. (2022). Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling. *IScience*, 25(1).
2. Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025). The tumor microenvironment's role in the response to immune checkpoint blockade. *Nature cancer*, 6(6), 924-937.
3. Bae, S., Lee, H., Na, K. J., Lee, D. S., Choi, H., & Kim, Y. T. (2025). STopover captures spatial colocalization and interaction in the tumor microenvironment using topological analysis in spatial transcriptomics data. *Genome Medicine*, 17(1), 33.
4. Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: the cancer-immunity cycle. *immunity*, 39(1), 1-10.
5. De Visser, K. E., & Joyce, J. A. (2023). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. *Cancer cell*, 41(3), 374-403.
6. Hu, G. S., Zheng, Z. Z., He, Y. H., Wang, D. C., Nie, R. C., & Liu, W. (2025). Integrated analysis of proteome and transcriptome profiling reveals pan-cancer-associated pathways and molecular biomarkers. *Molecular & Cellular Proteomics*, 24(3).
7. Knol, J. C., Lyu, M., Böttger, F., Monteiro, M. N., Pham, T. V., Rolfs, F., & Jimenez, C. R. (2025). The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets. *Cancer Cell*, 43(7), 1328-1346.
8. Li, Y., Jin, J., & Bai, F. (2022). Cancer biology deciphered by single-cell transcriptomic sequencing. *Protein & Cell*, 13(3), 167-179.
9. Li, Y., Porta-Pardo, E., Tokheim, C., Bailey, M. H., Yaron, T. M., Stathias, V., & Zhang, Z. (2023). Pan-cancer proteogenomics connects oncogenic drivers to functional states. *Cell*, 186(18), 3921-3944.
10. Liao, Y., Savage, S. R., Dou, Y., Shi, Z., Yi, X., Jiang, W., & Zhang, B. (2023). A proteogenomics data-driven knowledge base of human cancer. *Cell systems*, 14(9), 777-787.
11. Liu, H., Guo, Z., & Wang, P. (2024). Genetic expression in cancer research: challenges and complexity. *Gene reports*, 37, 102042.
12. Papaccio, F., García-Mico, B., Gimeno-Valiente, F., Cabeza-Segura, M., Gambardella, V., Gutiérrez-Bravo, M. F., & Castillo, J. (2023). Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. *Journal of Experimental & Clinical Cancer Research*, 42(1), 8.
13. Petralia, F., Ma, W., Yaron, T. M., Caruso, F. P., Tignor, N., Wang, J. M., & Zhang, Z. (2024). Pan-cancer proteogenomics characterization of tumor immunity. *Cell*, 187(5), 1255-1277.

14. Tang, W., Zhou, M., Dorsey, T. H., Prieto, D. A., Wang, X. W., Ruppin, E., & Ambros, S. (2018). Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival. *Genome medicine*, 10(1), 94.
15. Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., & Yu, G. (2021). clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *The innovation*, 2(3).
16. Zhang, Y., Chen, F., Chandrashekar, D. S., Varambally, S., & Creighton, C. J. (2022). Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. *Nature Communications*, 13(1), 2669.